One challenge to advancing Alzheimer's disease treatments is that many patients have mixed brain pathologies, meaning more than one disease process is affecting the brain. This can complicate diagnosis, clinical trial design and treatment development because a therapy targeting only one disease process may be less effective if another is also present.
One challenge to advancing Alzheimer's disease treatments is that many patients have mixed brain pathologies, meaning more than one disease process is affecting the brain.
This can complicate diagnosis, clinical trial design and treatment development because a therapy targeting only one disease process may be less effective if another is also present.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
One challenge to advancing Alzheimer's disease treatments is that many patients have mixed brain pathologies, meaning more than one disease process is affecting the brain. This can complicate diagnosis, clinical trial design and treatment development because a therapy targeting only one disease process may be less effective if another is also present.
Open the app view to save this story, compare related coverage, and continue from the same source.